EcoDrugPlus

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSOSIG00000022410
Gene Symbol: SERPINC1
1 Cross references
199 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSOSIG00000012892
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Si:dkey-91m11.5

Ensembl ID : ENSOSIG00000021051
Gene Symbol: SI:DKEY-91M11.5
1 Cross references
196 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSOSIG00000010490
Gene Symbol: SMO
1 Cross references
203 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSOSIG00000006061
Gene Symbol: SMO
1 Cross references
203 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSOSIG00000008348
Gene Symbol: SCN12AA
1 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSOSIG00000010858
Gene Symbol: SCN8A
1 Cross references
216 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSOSIG00000003200
Gene Symbol: SLC10A2
1 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSOSIG00000006957
Gene Symbol: SLC18A2
1 Cross references
216 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSOSIG00000009967
Gene Symbol: SLC29A1
1 Cross references
210 Possible Orthologues:

Solute Carrier Family 29 Member 1a

Ensembl ID : ENSOSIG00000004607
Gene Symbol: SLC29A1A
1 Cross references
209 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSOSIG00000015852
Gene Symbol: SLC5A1
1 Cross references
247 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).